JAK1 Double Nickase Plasmid (h): sc-400439-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- JAK1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- JAK1 Double Nickase Plasmid (h) and JAK1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting JAK1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: JAK1 Antibody (B-3): sc-376996
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
JAK1 Double Nickase Plasmid (h) | sc-400439-NIC | 20 µg | $410.00 | |||
JAK1 Double Nickase Plasmid (h2) | sc-400439-NIC-2 | 20 µg | $410.00 |
Janus kinase 1 (JAK1) is a non-receptor tyrosine kinase that couples cytokine receptors to downstream transcriptional programs, most prominently through the JAK–STAT pathway. In human cells, JAK1 is essential for signaling by type I and type II interferons and multiple interleukins, enabling phosphorylation of STAT proteins and coordination of innate and adaptive immune responses. JAK1 activity also interfaces with MAPK and PI3K/AKT signaling to influence proliferation, differentiation, and apoptosis in a context-dependent manner. Dysregulated JAK1 signaling has been implicated in inflammation-associated phenotypes, immune evasion, and aberrant growth signaling, making it a common node for mechanistic studies in immunology and cancer biology.
JAK1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the JAK1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within JAK1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt JAK1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of JAK1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.